ProQR Therapeutics N.V(PRQR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.46 | Insider Own | 28.85% | Shs Outstand | 141.1M | Perf Week | 2.92% |
| Market Cap | 0.20B | Forward P/E | - | EPS next Y | -16.75% | Insider Trans | 2% | Shs Float | 100.4M | Perf Month | -14.55% |
| Enterprise Value | 0.08B | PEG | - | EPS next Q | -0.11 | Inst Own | 43.61% | Short Float | 2.9% | Perf Quarter | -20.79% |
| Income | -0.05B | P/S | 9.3 | EPS this Y | -5.43% | Inst Trans | 20.57% | Short Ratio | 3.48 | Perf Half Y | -8.44% |
| Sales | 0.02B | P/B | 2.19 | EPS next 5Y | 11.2% | ROA | -31.23% | Short Interest | 2.91M | Perf YTD | -30.2% |
| Book/sh | 0.64 | P/C | 1.49 | EPS past 3/5Y | 21.8% 15.68% | ROE | -57.88% | 52W High | -53% ($3.00) | Perf Year | -50.53% |
| Cash/sh | 0.95 | P/FCF | - | Sales past 3/5Y | 68.13% - | ROIC | -48.66% | 52W Low | 17.5% ($1.20) | Perf 3Y | 20.51% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -4.53% | Gross Margin | 85% | Volatility(W/M) | 8.5% 6.52% | Perf 5Y | -81.97% |
| Dividend TTM | - | EV/Sales | 3.75 | Sales Y/Y TTM | 19.49% | Oper. Margin | -234.12% | ATR (14) | 0.1 | Perf 10Y | -74.13% |
| Dividend Ex-Date | - | Quick Ratio | 3.49 | EPS Q/Q | 29.54% | Profit Margin | -229.34% | RSI (14) | 41.43 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.49 | Sales Q/Q | 135.4% | SMA20 | -4.13% ($1.47) | Beta | 0.26 | Target Price | $8.39 |
| Payout | - | Debt/Eq | 0.17 | Earnings | 2026/8/13 | SMA50 | -21.21% ($1.79) | Rel Volume | 1.02 | Prev Close | $1.34 |
| Employees | - | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | 28.97% 122.24% | SMA200 | -16.76% ($1.69) | Avg Volume(3M) | 0.84M | Price | $1.41 |
| IPO | 2014/9/18 | Option/Short | Yes/Yes | Trades | 2404 | Volume | 852,442 | Change | 5.22% |
🧬 ProQR Therapeutics is a Netherlands-based RNA therapeutics company. It develops treatment candidates for genetic and rare diseases based on its proprietary Axiomer RNA editing platform, and is regarded as a small biotech focused on expanding its early-stage clinical pipeline.
Over the past 1 year, on the lower side
53% below its 1-year high.
Traded about as much as usual. That is 102% of its average volume.
PRQR has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -5.4% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $930. Peers typically go for $1,089.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -82.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 43.6%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
QQQS Invesco NASDAQ Future Gen 200 ETF <0.01% It ranks #302 of 594 in the industry
Based on market cap of $199M.
RNAC#300 Cartesian Therapeutics Inc $202M PER - 
ACOG#301 Alpha Cognition Inc $200M PER - PRQR#302 ProQR Therapeutics N.V $199M PER - 
WHWK#303 Whitehawk Therapeutics Inc $197M PER - 
BCYC#304 Bicycle Therapeutics Plc ADR $195M PER - 
FAQ
What kind of company is PRQR?
PRQR belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PRQR?
The market cap of PRQR is approximately $199M, ranking 4,032 within its sector.
What is the 52-week high and low for PRQR?
PRQR has recorded a 52-week high of $3.00 and a low of $1.20.
